54Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Puerto Rico
Neuroscience Intelligence
Puerto Rico neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #48 of 50 · Data maturity A · Research score 26.7 · Data confidence 100.0 / 100 · Snapshot 2026-10-12 03:36 UTC.
12Recruiting trials
3Publications
8Institutions
Executive interpretation
Puerto Rico ranks #48 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Eli Lilly and Company83 recruiting
Novartis Pharmaceuticals41 recruiting
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.40 recruiting
Pfizer30 recruiting
AbbVie30 recruiting
Novo Nordisk A/S30 recruiting
GlaxoSmithKline30 recruiting
Axsome Therapeutics, Inc.20 recruiting
Hoffmann-La Roche20 recruiting
Kodiak Sciences Inc20 recruiting
Disease activity
Alzheimers12trials
Epilepsy5trials
Pain Neuropathy5trials
Multiple Sclerosis3trials
Parkinsons3trials
Stroke2trials
Als2trials
Depression2trials
Other Neurology2trials
Schizophrenia2trials
Research institutions
Puerto Rico Department of HealthOpenAlexlinked institution
Ponce Health Sciences UniversityOpenAlexlinked institution
San Juan Bautista School of MedicineOpenAlexlinked institution
Universidad MetropolitanaOpenAlexlinked institution
University of Puerto Rico SystemOpenAlexlinked institution
University of Puerto Rico at Río PiedrasOpenAlexlinked institution
University of Puerto Rico, Medical Sciences CampusOpenAlexlinked institution
University of Puerto Rico at PonceOpenAlexlinked institution
Clinical evidence trail
NCT07684235Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)RECRUITING
NCT07641517A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis PainRECRUITING
NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RECRUITING
NCT06869785Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of OfatumumabACTIVE_NOT_RECRUITING
NCT06564974Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMITRECRUITING
NCT06223958Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular DegenerationACTIVE_NOT_RECRUITING
NCT05986292A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic PainRECRUITING
NCT05980949Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)RECRUITING
NCT05552157A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic MutationRECRUITING
NCT05269394Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)ACTIVE_NOT_RECRUITING
NCT05026866A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)ACTIVE_NOT_RECRUITING
Research evidence trail
OPENALEXMicrostimulation reveals opposing influences of prelimbic and infralimbic cortex on the expression of conditioned fear2006-11-01
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.